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Abstract 
High rates of lethal outcome in tumour metastasis are associated with the acquisition of invasiveness 
and chemoresistance. Several clinical studies indicate that E2F1 overexpression across high-grade 
tumours culminates in unfavourable prognosis and chemoresistance in patients. Thus, fine-tuning 
the expression of E2F1 could be a promising approach for treating patients showing 
chemoresistance.  
Methods: We integrated bioinformatics, structural and kinetic modelling, and experiments to study 
cooperative regulation of E2F1 by microRNA (miRNA) pairs in the context of anticancer 
chemotherapy resistance. 
Results: We showed that an enhanced E2F1 repression efficiency can be achieved in 
chemoresistant tumour cells through two cooperating miRNAs. Sequence and structural 
information were used to identify potential miRNA pairs that can form tertiary structures with E2F1 
mRNA. We then employed molecular dynamics simulations to show that among the identified 
triplexes, miR-205-5p and miR-342-3p can form the most stable triplex with E2F1 mRNA. A 
mathematical model simulating the E2F1 regulation by the cooperative miRNAs predicted enhanced 
E2F1 repression, a feature that was verified by in vitro experiments. Finally, we integrated this 
cooperative miRNA regulation into a more comprehensive network to account for E2F1-related 
chemoresistance in tumour cells. The network model simulations and experimental data indicate 
the ability of enhanced expression of both miR-205-5p and miR-342-3p to decrease tumour 
chemoresistance by cooperatively repressing E2F1.  
Conclusions: Our results suggest that pairs of cooperating miRNAs could be used as potential 
RNA therapeutics to reduce E2F1-related chemoresistance. 










Tumour metastasis continues to be the most 
significant problem in the field of cancer. The 
increasingly high rates of therapy failure and lethal 
outcome associated with tumour metastasis rely on 
the acquisition of invasiveness, early metastatic 
dissemination of tumour cells from their primary sites 
and generation of chemoresistance (1, 2). The 
underlying mechanisms for tumour metastasis and 
chemoresistance are not fully understood. However, 
the search for effective counter measures is an active 
field of research in molecular oncology as there is an 
urgent need for new forms of therapies or 
co-adjuvants able to sensitize tumour cells to existing 
therapies. In this context, therapeutic strategies 
aiming to modulate miRNA activity have gained 
popularity and are showing the first signs of success, 
as miRNAs have been found to be massively involved 
in the regulation of human cancers (3). These 
non-coding RNA transcripts can regulate a large 
number of mRNA targets, which possess imperfectly 
complementary binding sites in their 3’ untranslated 
regions (UTRs) (4). Therefore, the repressive effect of 
one miRNA on a single target is often rather mild and 
off-target effects are hindering effective miRNA 
replacement therapies (5,6). However, several studies 
have shown that an effective target regulation can be 
achieved through concerted miRNA regulation, 
where the phenomenon of synergistic regulation by a 
pair of miRNAs can significantly enhance the 
efficiency of target repression (7-14). We have shown 
previously that many genes are targets of cooperating 
miRNA pairs (15). This mechanism facilitates a 
fine-tuned post-transcriptional gene regulation in a 
cell-context-dependent manner (8). 
In many cancer entities, the transcription factor 
E2F1, a versatile trans-acting protein involved in 
many critical cellular processes, has been found to be 
strongly up-regulated in aggressive tumours and 
metastases co-occurring with therapy failure and poor 
patient survival prognosis (16, 17). It has been 
previously shown that E2F1 can play an important 
role in the emergence of aggressive tumour cell 
phenotypes (18-20). More specifically, we have 
demonstrated that E2F1 induces resistance to single or 
multiple anti-cancer drugs by targeting ABC 
transporter family members and Bcl-2 via a network 
that involves E2F1, p73, the N-terminally truncated 
p73 isoform DNp73 (also known as inhibitor of p73) 
and miR-205-5p. This work was motivated by 
mathematical simulations and was experimentally 
confirmed. Our results indicate that the interplay 
between E2F1 and miR-205-5p realized by a negative 
feedback loop is crucial to induce chemoresistance in 
tumour cells.  
In this article, we integrated bioinformatics, 
structural and kinetic modelling, and experiments to 
study the effects of synergistic regulation by miRNA 
pairs on the expression of E2F1 and possible 
implications for drug-resistant tumour cells. Our 
computational predictions suggest that miR-205-5p 
and miR-342-3p achieve an enhanced repressive effect 
on E2F1 expression in a cooperative manner. We 
validated our predictions in H1299 cells, an 
aggressive human non-small cell lung carcinoma cell 
line. Then, we integrated miRNA cooperativity into a 
kinetic model of E2F1-mediated chemoresistance. 
Model-based simulations and experimental data show 
that synergistic E2F1 regulation by miR-205-5p and 
miR-342-3p can abrogate chemoresistance in 
aggressive tumour cells. Taken together, our results 
suggest that suppression of E2F1 expression by 
cooperating miRNA pairs can be used to sensitize 
tumour cells to chemotherapy. 
Materials and Methods 
miRNA regulation of E2F1 
We derived experimentally confirmed 
miRNA-E2F1 interactions from miRTarBase, a 
manually curated, literature-based database of 
validated miRNA-target interactions based on 
different experimental methods (release 6.0) (21). For 
our analysis we considered only those interactions 
that were confirmed by reporter assay experiments. 
We complemented the set of validated miRNAs 
regulating E2F1 by predictions from the highly 
sensitive miRNA-target prediction algorithm 
miRanda (August 2010 Release; Figure 1) (22). We 
considered only target sites of conserved miRNAs, 
with good miRSVR scores (≤ -0.1). The mirSVR score, 
which is applied in miRanda predictions, is based on a 
support vector regression classifier that was trained 
with data from miRNA transfection experiments. 
Sequence, contextual and structural features of 
predicted miRNA target sites taken from 
down-regulated target mRNAs were incorporated 
into this classification system where scores correlate 
with the extent of target down-regulation. 
Information on miRNA families was extracted from 
the miRBase database (release 21) (23). 






Figure 1. E2F1 targeting miRNAs. (A) In total 26 miRNAs were predicted to be post-transcriptional regulators of E2F1 expression. The figure shows the 
location of the binding sites and highlights putatively cooperating miRNAs (the transparent boxes on top). The transparent box indicates the location of the miRNAs 
that could putatively cooperate with miR-205-5p in repressing E2F1. (B) Conservation of miRNA binding sites. The green track in this UCSC genome browser 
snapshot shows the PhastCons score (100 vertebrate conservation track) indicating the evolutionary conservation of miRNA binding sites in the 3’ UTR of E2F1. The 
genomic region shown includes binding sites of miR-205-5p and putatively coopering miRNAs (black bars). A multiple sequence alignment of some related species is 
shown in the bottom track. The E2F1 gene is locate on the negative strand. While the 3′ UTR sequence in (A) is in 5′ to 3′ orientation, the reading direction in the 
UCSC genome browser snapshot (B) is opposite to that. 
 
Secondary structures of RNA complexes 
Secondary structures of RNA triplexes 
composed of two putatively cooperating miRNAs and 
the E2F1 mRNA were predicted using the E2F1 3’ 
UTR sequence extracted from the RefSeq gene track of 
the UCSC table browser (GRCh37/hg19) (24) and the 
mature miRNA sequences from the miRBase database 
(23). Secondary structures were computed using the 
mfe tool from the NUPACK software package (Table 
1) (25). In NUPACK, the full partition function (except 
for pseudo knots) of RNA complexes is computed in 
dilute solution. For the visualization of the RNA 
complexes we used the RNA structure drawing tool 
VARNA (version 3.9) (26). 
RNA complex equilibrium concentrations 
For the RNA triples involving the E2F1 mRNA 
and two putatively cooperating miRNAs, we 
computed the equilibrium concentrations of all 
monomers and possible complexes formed by these 
RNA molecules in dilute solution. For this purpose 
we made use of the tools named as complexes and 
concentrations, which are also part of the NUPACK 
package (25). The equilibrium concentrations are 
based on initial concentrations of 100 nM per RNA 
species. The equilibrium concentrations were 
computed by a partition function algorithm as 
described in (27). 





Table 1. miRNA pairs cooperating in the regulation of E2F1.  











     
Structure pattern target 
self-complementarity 
canonical triplex target self-complementarity canonical triplex canonical triplex 
Seed distance (nt) 32 27 33 27 27 
∆G (kcal/mol) -50.56 -45.26 -44.86 -44.66 -42.76 
∆∆G (kcal/mol) -20.28 -14.78 -12.98 -14.18 -12.28 
Potential energy 
(kcal/mol) 
-8241.33 -7040.79 -7623.90 -6841.37 -7064.68 
Equilibrium 
concentration (nM) 
99.95 94.93 47.05 88.88 64.36 
The second row shows the local secondary structure for the predicted RNA triplexes (grey: mRNA, green: miR-205-5p, red: other miRNAs). Seed distance: the distance 
between the seed sites of the miRNAs in the 3’ UTR of E2F1. ∆G: the change in Gibbs free energy when the miRNA pairs and the E2F1 mRNA form the triplex 
(miRNA1/miRNA2/mRNAE2F1). ∆∆G: the free energy gained by triplex formation compared to the duplex (miRNA/mRNAE2F1) showing smaller ∆G. Potential energy: the 
calculated energy in the 3D structure of the triplexes. Equilibrium concentration: the equilibrium concentrations of RNA triplexes computed by a partition function algorithm 
(see Materials and Methods). 
 
3D structure modelling and molecular 
dynamics simulations 
We first constructed the initial 3D structure of 
the RNA triplexes (mRNAE2F1/miRNA1/miRNA2) as 
well as their two intrinsic RNA duplexes 
(mRNAE2F1/miRNA1 and mRNAE2F1/miRNA2) using 
RNAComposer web server (28). Then, these 
complexes were processed as described in our 
previous publication (15) and further optimized using 
Smart Minimizer protocol in BIOVIA® Discovery 
Studio 4.5 (29, 30). Finally, molecular dynamics 
simulations were carried out using the Standard 
Dynamics Cascade protocol in BIOVIA® DS 4.5 in four 
steps: (i) minimization; (ii) heating and cooling; (iii) 
equilibrium run; and (iv) production run, for all the 
potential cooperating miRNAs complexed with the 3’ 
UTR of E2F1 (Figure 2). The detailed procedure of the 
molecular dynamics simulations can be found in 
Supplementary Material. 
Mathematical modelling 
To elaborate on the mechanism by which E2F1 is 
repressed by cooperative miRNA pairs, we developed 
a kinetic model of ordinary differential equations. The 
model accounts for the formation of complexes, 
including two RNA duplexes and one RNA triplex, by 
the E2F1 mRNA and the two cooperative miRNAs, 
and the disassociation of these complexes as a result 
of reversible binding processes between miRNAs and 
their target mRNAs. The model parameters were 
characterized using the RNA complex equilibrium 
concentration results and the change of Gibbs free 
energy (∆G) of RNA triplexes that were calculated 
from their secondary structures. The data-driven 
model was used to estimate repression efficiency of 
the cooperative miRNAs on E2F1 (Figure 3). In 
addition, the model accounting for the cooperative 
repression of E2F1 by miR-205-5p and miR-342-3p 
was characterized using the in vitro data, and the 
simulated E2F1 protein level was compared with the 
Western blot data showing the repression of E2F1 by 
individual and cooperative miRNA repression 
(Figure 4C). The details of model description, model 
calibration and model simulation can be found in 
Supplementary Material. 
To simulate the effect of miR-205-5p and 
miR-342-3p on the response of tumour cells to 
chemoresistance, we integrated the cooperative 
regulation of E2F1 by the two miRNAs into a 
published kinetic model (18). The expanded model 
accounts for the temporal dynamics of a regulatory 
network, whose activation is triggered after 
anticancer drug administration and modulates a 
phenotypic response in a population of tumour cells. 
The values of original model parameters were taken 
from the publication and the new ones accounting for 
the cooperative repression of E2F1 by the two 
miRNAs were characterized using the experimental 
data. The model was simulated to show the effects of 
the cooperative miRNA repression on drug resistance 





in tumour cells with overexpressed E2F1 (Figure 5). 
The details of model description, model calibration 
and model simulation can be found in Supplementary 
Material. The MATLAB files used for running the 
simulations can be found at goo.gl/ZdAhdY. 
 
 
Figure 2. Intermolecular H-bonds between mRNA and miRNAs in RNA triplexes during 1,000 ps MDS run. (A) The solid lines indicate the number of H-bonds 
when both miRNAs are associated with E2F1 mRNA, while the extended dotted line shows the number of H-bonds between the remaining miRNAs (underlined) and the mRNA. 
For each triplex, the underlined miRNA first disassociates from the mRNA at the time point indicated by the correspondingly coloured arrow. (B) Interactions between the E2F1 
3′ UTR (grey), miR-342-3p (green) and miR-205-5p-5p (red) in a 3D model. The intermolecular H-bonds between the three RNA species are shown as green dotted lines. The 
simulation also indicates that miR-205-5p and miR-342-3p interact with each other through H-bonds (red circle), which may contribute to the better stability of this triplex over 
others. 
 
Figure 3. Simulations of E2F1 repression by cooperating miRNA pairs. The plots show the expression levels of E2F1 (0: silencing; 1: non-repression) for different 
combinations of the miRNA transcriptional activation (denoted by 𝑻𝑻𝑻𝑻𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝟏𝟏 and 𝑻𝑻𝑻𝑻𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝟐𝟐 in the model). The nominal value of the miRNA transcriptional activation is 1, and 
values smaller than 1 indicate down-regulation while values greater than 1 represent up-regulation of the miRNA. The four reference points represent normal expression of 
miRNAs (dot), strong up-regulation of one miRNA (triangles) and moderate up-regulation of both miRNAs (diamond). The numbers denote the gain of E2F1 repression efficiency 
while increasing miRNA expression levels.  






Figure 4. miR-205-5p and miR-342-3p cooperate in the regulation of E2F1. (A) Quantification of miRNA levels after individually or co-transfecting miR-205-5p and 
miR-342-3p expression plasmids into H1299 and SK-Mel-147 cells. (B) Relative luciferase activity after co-transfection of E2F1-3’ UTR (0.5 μg) and miR-205-5p/miR-342-3p 
plasmids into H1299 and SK-Mel-147 cells. (C) Western blot showing E2F1 protein expression after single or combined miR-205-5p/miR-342-3p overexpression in H1299 and 
SK-Mel-147 (top). The E2F1 protein levels (data) were quantified and compared with model simulations (model) showing the cooperative E2F1 repression by miR-205-5p and 
miR-342-3p (bottom). Actin was used as loading control and for normalising the protein expression data. Plasmid concentrations for miRNA expression are indicated in the 
corresponding figures. The details of the model simulation can be found in Supplementary Material. (D) Multidose combinations of miR-205 and miR-342 for repressing E2F1. 
Relative luciferase activity was measured after co-transfection of E2F1-3’ UTR and miR-205-5p/miR-342-3p plasmids into H1299 and SK-Mel-147 cells. For the individual 
treatments, 0.25 µg, 0.5 µg, or 1 µg of miR-205 or miR-342 plasmid were transfected into cells, and for the combined treatment, 0.25 µg, 0.5 µg, or 1 µg of both miRNA plasmids 
were co-transfected. (E) The table shows the calculated fraction affected (fa) by the individual miRNA or combined miRNA treatments and the corresponding combination 
indexes (CI) of the combined treatments (synergism: CI < 1; antagonism: CI > 1). The estimated parameter values can be found in Table S5. Data shown in the bar plots are mean 
± SD (n = 3). 
 
Cell culture 
H1299 (ATCC) and SK-Mel-147 (obtained from 
M. Soengas, Department of Dermatology, University 
of Michigan, Comprehensive Cancer Center, 
AnnArbor, MI) were maintained in Dulbecco’s 
modified Eagle’s medium (high glucose, 4.5 g/L) 
containing 2 mM L-glutamine, 1 mM sodium 
pyruvate, supplemented with 10% FCS, 0.1 mM 
non-essential amino acids, 50 U/mL penicillin and 50 
μg/mL streptomycin. Cell lines were tested for 
mycoplasma contamination prior to the experiments 
according to the manufacturer’s instructions (Venor 
GeM Classic, Minerva Biolabs). 






Figure 5. Effects of cooperative E2F1 repression on chemoresistance. (A) Biochemical reaction network underlying the kinetic model of E2F1-mediated drug resistance. (B) 
Illustration of a typical model simulation, accounting for the temporal dynamics of E2F1 protein, miR-205-5p, Harakiri protein (Hrk), BCL2 protein and the population of tumour cells (TC) 
before (shaded area) and after drug administration (white area). (C) Model predicted values of E2F1, miR-205-5p and the ratio between p73 and DNp73 for different combinations of E2F1 
and miR-342-3p expression levels, whose corresponding variables FSE2F1 and FSmiR342 were iteratively modified in the specified intervals. The highlighted and indexed areas correspond to the 
description in the main text. (D) Predicted tumour cell population size in non-genotoxic drug stimulation conditions (left) and predicted fraction of surviving tumour cells 48 h after genotoxic 
drug administration (right). The enclosed numbers indicate the transition of tumour growth rate under different biological conditions. 
 
TaqMan®MicroRNA single assays and PCR 
In general, large and small RNA were extracted 
using the NucleoSpin® miRNA kit 
(MACHEREY‐NAGEL). miRNA expression levels 
were measured using TaqMan®MicroRNA single 
assays and the 7900HT Fast Real‐Time PCR System 
(Applied Biosystems). For expression analysis, the 
comparative CT method was used with RNU6B as 
endogenous control (19).  





Cloning of expression plasmids, 3′ UTR 
constructs and luciferase reporter assay 
miR-205-5p and miR-342-3p were amplified by 
PCR using genomic DNA as template and cloned into 
the pWPXL vector. pEZX-MT01 vector expressing the 
3′ UTR of E2F1 was purchased from GeneCopoeia. 
For luciferase assays, cells were transfected using 
Turbofect (Thermo Scientific). Luciferase activity was 
measured 36 h after transfection using the Luciferase 
Reporter Assay System (Promega) and normalized to 
total protein concentration in cell extract (19).  
Western blotting and immunofluorescence 
Protein analysis was performed as described 
previously (31). Briefly, cell lysis was carried out 
using RIPA buffer, containing PhosSTOP Phosphatase 
Inhibitor Cocktail (Roche), and protein concentration 
was determined by Bradford assay (Bio‐Rad). The 
same quantity of different protein samples was 
separated by SDS-PAGE and transferred to 
nitrocellulose membranes (Amersham Biosciences) 
(31). Selected proteins were detected by the use of 
specific antibodies for E2F1 (KH‐95, BD Biosciences), 
BCL2 (AB1, Merck), Bax (D2E11, Cell Signaling), and 
actin (Sigma) as well as their corresponding 
HRP‐conjugated secondary antibodies. ECL Plus 
Western Blotting Detection Reagents (GE Healthcare) 
allowed detection of HRP activity with the 
ChemiDocTMTouch Imaging System (BioRad). 
Hoechst staining 
For quantification of apoptotic cells after miRNA 
perturbation and cisplatin treatment, cells were 
stained with Hoechst 33342 (2 µg/mL) dye. Images 
were evaluated using the ImageJ software. 
Combination index 
To determine whether or not the combined 
miRNA treatment has a synergistic effect on E2F1 
repression or can increase chemosensitivity of tumour 
cells, we performed a quantitative analysis of 
dose-effect relationships using the method proposed 
by Chou (32, 33) and computed the combination index 
(CI) using CompuSyn (www.combosyn.com). The 
combination index of the combined miRNA treatment 


















where D<miR1, miR2> represent the concentrations of 
miRNAs used in the experiments, 𝐷𝐷<𝑚𝑚𝑚𝑚𝑚𝑚1,𝑚𝑚𝑚𝑚𝑚𝑚2>𝑚𝑚  are the 
median-effect doses of miRNAs (i.e., the dose of a 
miRNA leading to a 50% reduction of E2F1 
expression), and m<miR1,miR2> are kinetic orders that 
determine the slope of the median-effect curves. Both 
𝐷𝐷<𝑚𝑚𝑚𝑚𝑚𝑚1,𝑚𝑚𝑚𝑚𝑚𝑚2>𝑚𝑚  and m<1, 2> are estimated from the 
calculated famiR and D used in the experiments. For the 
E2F1 luciferase assays, the fraction affected (fa) is 
calculated using the equation famiR = 1 - E2F1miR, where 
E2F1miR indicates the relative luciferase activity after 
co-transfection of a E2F1-3′ UTR reporter construct 
and miRNA plasmids into the tumour cells. For the 
chemosensitivity experiments, famiR indicates 
increased apoptosis of tumour cells relative to 
untreated cells that is divided by the apoptosis rate of 
cisplatin-treated cells and further normalized to the 
maximum apoptosis rate among all miRNA 
treatments. 
Results and Discussion 
Cooperative E2F1 regulation by miRNA pairs 
To overcome E2F1-mediated chemoresistance, 
we propose to employ a combinatorial treatment 
using a genotoxic drug and a miRNA adjuvant. The 
latter is to be realized through replacing miR-205-5p, 
an E2F1 suppressor undetectable in many aggressive 
tumours (19), with a cooperating miRNA pair to 
strengthen E2F1 repression efficiency and thereby 
reduce side effects caused by non-specific binding and 
exaggerated miRNA induction (8). 
Using the miRanda algorithm for miRNA target 
prediction, we identified 25 miRNAs, other than 
miR-205-5p, that are putative regulators of human 
E2F1 expression (Figure 1A). Each of these miRNAs is 
predicted to have one or more binding sites in the 3’ 
UTR of E2F1 and six of these interactions have been 
experimentally validated using reporter assays 
(21,34). According to Saetrom and colleagues (10) 
miRNA cooperativity can be observed when the seed 
binding sites of a pair of miRNAs are 13-35 nt apart. 
They derived this rule from controlled experiments in 
Renilla luciferase reporter constructs in which they 
cloned pairs of let-7 target sites with different seed site 
distances into the 3’ UTR (10). Using this rule and 
other analytical steps, we previously developed a 
computational workflow for the prediction of 
cooperating miRNA pairs (35). The workflow 
includes, after miRNA target site prediction and seed 
site distance discrimination, the prediction of the local 
secondary structure of putative miRNA triplexes 
composed of two potentially cooperating miRNAs 
and their mutual target mRNA (here E2F1). 
We applied this workflow in order to predict 
which miRNA pair can most efficiently suppress E2F1 
expression. As a result, we identified five miRNAs 
that putatively cooperate with miR-205-5p in the 
regulation of E2F1 (Figure 1A). Further analysis 
revealed that the identified miR-205-5p binding site is 
very well conserved (Figure 1B), suggesting its 





functional interaction with E2F1 mRNA that can lead 
to the repression of E2F1 (19). Interestingly, all the 
miRNAs associated within these cooperative pairs 
have separately been characterized as tumour 
suppressors in previous studies (36-40). 
According to our predictions, all five complex 
structures have a very low Gibbs free energy (ΔG < 
-42 kcal/mol) with preserved seed binding sites for 
both miRNAs in the triplex structure (Table 1). This 
suggests that all triplexes are thermodynamically 
stable, which is a prerequisite for effective 
miRNA-target regulation. Muckstein et al. (41) has 
shown that the efficiency of RNA interference 
correlates with the binding energies of miRNA target 
pairs, while other studies suggest that the seed 
binding is crucial for effective target regulation (42). 
We used the secondary structures as template for 
deriving the tertiary structure of the RNA triplexes to 
further corroborate a stable structure formation 
between the pairs of miRNAs and E2F1 mRNA (Table 
1). The workflow for modelling RNA triplex tertiary 
structures is described in the Materials and Methods 
section as well as in (15). Subsequently, we were 
interested in the likelihood of triplex formation 
involving the indicated RNA molecules. Based on a 
partition function, we computed the equilibrium 
concentrations of monomers (mRNAE2F1, miRNA1 and 
miRNA2) as well as possible complex species (i) 
miRNA1/miRNA2; (ii) miRNA1/miRNA1; (iii) 
miRNA2/miRNA2; (iv) mRNAE2F1/miRNA1; (v) 
mRNAE2F1/miRNA2; (vi) mRNAE2F1/mRNAE2F1; (vii) 
mRNAE2F1/miRNA1/miRNA2. The equilibrium 
concentrations (0-100 nM) of monomers and complex 
species enabled us to derive association rates for 
complex formation, which we used for the 
parameterization of small kinetic models of 
cooperative E2F1 regulation. RNA triples with a high 
triplex formation probability, i.e., high triplex 
equilibrium concentration, are likely to exhibit 
cooperative miRNA-target regulation (15). Based on 
the analytical steps performed we concluded that all 
five possible triplexes can indeed form stable 
secondary structures with preserved seed binding of 
the two miRNAs. However, one candidate triplex 
stands out. The triplex mRNAE2F1/miR-205-5p/miR- 
342-3p, has the lowest free energy in the predicted 
secondary structure (∆G = -50.56 kcal/mol). It also has 
the highest predicted equilibrium concentration (99.95 
nM; Table 1) among all E2F1 triplexes. 
Molecular dynamics simulations confirm that 
miR-205-5p, miR-342-3p and E2F1 mRNA 
form the most stable triplex among the 
candidates 
To substantiate the results from the previous 
steps we performed molecular dynamics simulations 
(MDS) for all five possible E2F1-miRNA triplexes 
identified and analysed their structural and 
thermodynamic properties. Stability of the RNA 
complexes was observed based on the intermolecular 
hydrogen bonds (H-bonds) formed between the 3′ 
UTR of E2F1 and targeting miRNA pairs during the 
MDS run (Figure 2A). The number of intermolecular 
H-bonds between miRNA and mRNA was also 
previously used to assess the miRNA binding 
characteristics in a MDS study (43). Our MDS indicate 
that the mRNAE2F1/miR-205-5p/miR-342-3p triplex 
was stable for the longest simulation runtime in 
comparison to the other triplexes (purple solid line in 
Figure 2A; the purple arrow on the x-axis indicates the 
time point where miR-205 dissociates from the 
triplex). We also observed additional intermolecular 
H-bonds between miR-205-5p and miR-342-3p along 
with H-bonds with mRNAE2F1, which might be one of 
the reasons for the better stability of this complex over 
others (Figure 2B). In particular, both miRNAs were 
associated to the E2F1 mRNA for ~560 ps, which is 
~140 ps longer than the second most stable RNA 
triplex mRNAE2F1/miR-205/miR-148a (green solid 
line in Figure 2A). Furthermore, after the 
disassociation of miR-205-5p from 
mRNAE2F1/miR-205-5p/miR-342-3p triplex, 
miRNA-342-3p continued to maintain intermolecular 
H-bonds with the E2F1 mRNA until 824 ps (indicated 
by the extended purple dotted line in Figure 2A). The 
least stable RNA triplex was 
mRNAE2F1/miR-205/miR-377 (red solid line that was 
the first one to end at ~180 ps after dissociation of 
miR-205 from this triplex in Figure 2A); however, the 
E2F1 mRNA and miR-377 formed the longest lasting 
duplex (red dotted line in Figure 2A) and maintained 
intermolecular H-bonds for the entire MDS runtime 
(1000 ps). We observed that the most stable RNA 
triplex mRNAE2F1/miR-205-5p/miR-342-3p has the 
minimum potential energy (-8241.33 kcal/mol; Table 
1), which is 617 kcal/mol less than the second most 
stable RNA triplex, i.e., 
mRNAE2F1/miR-205-5p/miR-377 (-7623.90 kcal/mol). 
Taken together, based on the secondary and 3D 
structure analyses, 
mRNAE2F1/miR-205-5p/miR-342-3p was found to be 
the most stable triplex among the five E2F1 RNA 
triplexes. This result suggests that these two miRNAs 
could be the most effective pair to induce cooperative 
E2F1 repression. 
Cooperating miRNAs have different 
repression effects on E2F1 
Kinetic modelling is a powerful tool to dissect 
the role of miRNAs in gene regulator networks and 





provides quantitative insights into the function of 
miRNAs in the regulation of gene expression (44, 45). 
In order to elaborate the effect of cooperative miRNA 
regulation on E2F1 concentration, we implemented 
for each of the predicted RNA triplexes a kinetic 
model describing miRNA-mediated E2F1 regulation 
(see Materials and Methods). The five parameterized 
models for all the possible cooperating pairs enabled 
us to determine which miRNA pair can efficiently 
regulate its mutual target gene E2F1. We simulated 
E2F1 repression by cooperating miRNA pairs, 
modulating miRNA transcriptional activation in a 
range between 10-1 and 102. The nominal value of 
miRNA transcriptional activation is 1, and values 
below 1 indicate a down-regulation of the miRNAs, 
while values above 1 represent an up-regulation of the 
miRNAs. Then, we computed the steady states of 
E2F1 for different combined expression levels of 
cooperative miRNAs and repression gains for four 
scenarios: (i) normal expression of both miRNAs, (ii) 
strong up-regulation of one of the two miRNAs and 
(iii) moderate up-regulation of both miRNAs in 
combination (Figure 3). The repression gain 
represents a measure for the efficiency gained in 
target repression by either overexpressing a single 
miRNA or by synergistic miRNA-target regulation. 
The simulations showed that all five miRNA pairs can 
regulate E2F1 expression in a synergistic manner and 
among them miR-205-5p and miR-342-3p have the 
strongest cooperative effect on E2F1 expression. More 
specifically, the most efficient target repression is 
achieved when miR-205-5p and miR-342-3p are 
simultaneously upregulated (the lines along the 
diagonal direction in Figure 3). A comparable target 
repression level can be achieved with one active 
miRNA only in case of very strong up-regulation (the 
vertical and horizontal lines in Figure 3). However, 
high overexpression of a single miRNA is unwanted 
as our approach aims to avoid off-target effects by 
applying lower miRNA concentrations. In addition, 
the model predicted discrepant E2F1 repression 
efficiencies when the expression of miR-205-5p is 
upregulated alone and the expression of its 
cooperating miRNAs is unchanged (the horizontal 
lines in Figure 3). This suggests that the individual 
repression efficiency of miR-205-5p on E2F1 may 
change when it cooperates with different miRNAs 
having different binding affinities to the mRNA of 
E2F1. 
In vitro experiments verify the synergistic 
effect on E2F1 repression by miR-205 and 
miR-342 
To verify the computational results that showed 
the cooperativity of miR-205-5p and miR-342-3p in 
E2F1 repression, we measured endogenous 
concentrations of both miRNAs and after 
overexpression in both cell lines (Figure 4A) and 
performed luciferase assays and immunoblotting in 
tumour cells (see Materials and Methods). In 
luciferase assays we co-transfected H1299 and 
SK-Mel-147 cells with the 3′ UTR of E2F1 and 
miR-205-5p/miR-342-3p expression plasmids. We 
observed a decreased luciferase activity when we 
co-transfected miR-205 and miR-342 (each 0.5 μg) in 
comparison to the transfection of either miR-205 or 
miR-342 (each 1 μg; Figure 4B). The cooperative effect 
could be observed both on mRNA (Figure S1) and 
protein (Figure 4C, top panels) levels, showing a 
strongly reduced E2F1 expression after combined 
overexpression of miR-205-5p/miR-342-3p in 
comparison to the overexpression of each miRNA 
individually. In addition, we showed that both 
miRNAs are expressed at low levels in various 
aggressive cancer cells including H1299 and 
SK-Mel-147 cells (Figure S2). Published high 
throughput data showed that the other 
miR-205-cooperating miRNAs (miR-148a/b-3p, 
miR-377-3p and miR-152-3p) are also expressed at low 
or negligible levels in H1299 cells (46). This excludes 
the possibility that E2F1 is regulated by the other 
miRNAs that are predicted to cooperate with 
miR-205. These data are also consistent with our 
model simulations that show the strongest 
down-regulation of E2F1 protein when both miRNAs 
are simultaneously upregulated to a medium level 
(Figure 4C, bottom panels). This demonstrates the 
ability of the model for making accurate predictions 
about E2F1 repression by the two miRNAs. We 
performed additional luciferase assays to determine 
whether the synergistic effect can be observed for 
different miRNA concentrations (Figure 4D). The 
results were used to calculate the combination index 
(CI) to quantify the synergism of the combined 
miRNA treatment (see Materials and Methods). The 
index is recognized as the standard measure of 
combination effect that indicates a greater (CI < 1) or 
smaller (CI > 1) effect than the expected additive effect 
(32, 47). When both miRNAs (each 0.25 μg or 0.5 μg) 
were co-transfected into H1299 cells, the combined 
miRNA treatment showed a mild synergistic effect (CI 
= 0.785 or 0.835) on the repression of E2F1, and with 
increasing amounts of both miRNAs (e.g. 1 μg each) a 
very strong synergism was achieved (CI = 0.018; 
Figure 4E). In SK-Mel-147 cells, combined miRNA 
transfection showed synergistic effects on E2F1 
repression (CI = 0.255, 0.276, or 0.220 for 0.25 µg, 0.5 
µg, or 1 µg miRNA, respectively). Taken together, the 
results indicate that miR-205-5p and miR-342-3p can 
cooperate to induce synergistic repression of E2F1 in 





tumour cells, whereas the degree of synergism seems 
to be cell context dependent. 
Tackling chemoresistance through 
cooperative E2F1 regulation in tumour cells  
Our analyses indicate that miR-205-5p and 
miR-342-3p can cooperatively repress E2F1 
expression. Importantly, this is consistent with 
published experimental data showing that the 
repression ability of miR-205-5p alone is weak and 
therefore extreme overexpression of miR-205-5p is 
required to achieve an effective repression of E2F1 in 
tumour cells (48). Extreme overexpression of a single 
miRNA can lead to off-target effects (6). 
To investigate whether miRNA cooperativity can 
help to abrogate chemoresistance in tumour cells we 
integrated cooperative target regulation into a kinetic 
model of E2F1-mediated chemoresistance that 
includes the p73/DNp73 regulatory circuitry 
previously described in Vera et al. (18). The expanded 
model includes thirteen ordinary differential 
equations (see Materials and Methods). A network 
representation of the model is shown in Figure 5A. 
Model simulations were used to assess the 
downstream effect of miR-205-5p and miR-342-3p 
regulation, individually and in cooperation, on E2F1 
expression and drug-induced apoptosis. Furthermore, 
we investigated the dynamics under growth and 
chemotherapy conditions of a population of tumour 
cells (denoted by the model variable TC) whose 
response to drug treatment is mediated by the 
described regulatory network. Given that 
overexpression of E2F1 is associated with 
chemoresistance in tumour cells (19,49) and that 
miR-342-3p down-regulation has been associated with 
the emergence of cancer cell phenotypes resistant to 
anticancer drugs (50), we simulated the model while 
iteratively modifying model variables that modulate 
the expression levels of E2F1 mRNA (FSE2F1) and 
miR-342-3p (FSmiR342). These variables can be regarded 
as experimental approaches (e.g., a plasmid or viral 
vector carrying miRNA mimics or anti-miRNA 
oligonucleotides) that can change the expression level 
of a specific gene. Then, the predicted E2F1 protein 
expression levels, miR-205-5p levels, the ratio 
between p73 and DNp73, and the size of the tumour 
cell population were visualized (Figure 5C, D). The 
detailed description of the model simulations can be 
found in Supplementary Material. 
The simulation results indicate that the 
combination of the feedback loop structure of the 
system and the cooperative E2F1 repression by 
miR-205-5p and miR-342-3p can generate a non-linear 
regulation landscape for the system (Figure 5C). For 
low and medium values of the E2F1 synthesis rate, the 
synergy between miR-205-5p and miR-342-3p 
succeeds in repressing E2F1 and keeping E2F1 protein 
expression at low values (area 1 in Figure 5C left). 
Interestingly, model predictions indicate that high 
expression of miR-342-3p is sufficient to induce strong 
E2F1 repression even when the feedback loop 
structure of the system induces a significant reduction 
in miR-205-5p expression levels (area 2 in Figure 5C 
middle). However, in case of high E2F1 mRNA 
synthesis rates, the balance between p73-induced 
positive and DNp73-induced negative regulation of 
miR-205-5p expression is distorted (area 3 in Figure 
5C right). Hence, miR-205-5p expression becomes 
inhibited by high levels of DNp73 while the 
expression level of miR-342-3p is low (area 3 in Figure 
5C middle). With the increased miR-342-3p 
expression, miR-205-5p expression can recover due to 
the loss of E2F1 through an effective cooperative 
repression (area 4 in Figure 5C left and middle).  
Furthermore, our simulations predict that 
tumour cell population growth can be controlled by 
the effect of miR-205-5p and miR-342-3p cooperativity 
(Figure 5D left). More specifically, the proliferation of 
tumour population starts increasing with the 
up-regulation of the E2F1 expression level and 
becomes uncontrollable when the E2F1 expression 
level crosses certain thresholds (①→②). The tumour 
growth is relieved while increasing the expression 
level of miR-342-3p that can cooperate with 
miR-205-5p to suppress E2F1 (②→③). Moreover, 
under genotoxic drug administration the cooperating 
miRNAs enhance drug-induced apoptosis of tumour 
cells even in case of high E2F1 expression levels, 
resulting in a reduced tumour cell population (Figure 
5D right). In particular, the controllable tumour cells 
(growth rate ≤ 150%) can be eliminated as a result of 
the cooperative miRNA repression on E2F1 (the cyan 
area); however, the tumour cells (growth rate > 150%) 
having extremely high E2F1 levels or short of 
miR-324-3p for the cooperative repression still show 
resistance to the drug effect (the pink area). Taken 
together, these results indicate that the synergistic 
repression of E2F1 by miR-205-5p and miR-342-3p has 
the potential to repress the growth of tumour cell 
populations, but can also sensitize tumour cells to the 
administration of anticancer drugs. This suggests that 
therapies combining the administration of genotoxic 
drugs with miR-342-3p and miR-205-5p may enhance 
the drug-induced apoptosis of tumour cells with 
abnormally high expression levels of E2F1. 
Experimental validation of increased 
chemosensitization through E2F1 suppression 
by cooperating miRNAs 
To demonstrate that suppression of E2F1 





expression by the cooperating miRNA pair can be 
used to sensitize tumour cells to chemotherapy, we 
overexpressed miR-205-5p and miR-342-3p either 
alone or both together in the absence and presence of 
different cisplatin concentrations (5 µM - 60 µM) and 
quantified the amount of apoptotic cells using 
Hoechst 33342 live-cell staining and fluorescence 
microscopy. As shown in Figure 6A, individual 
miRNA transfection (each at 0.5 µg) leads to an almost 
5.5-fold increase of apoptotic cells in combination 
with cisplatin treatment.  
 
Figure 6. The effect of miR-205-5p and miR-342-3p on tumour cell chemosensitization. (A) Cisplatin (cDDP) treatment of chemoresistant H1299 with single 
miR-205-5p (0.5 µg or 1 µg plasmid), miR-342-3p (0.5 µg or 1 µg plasmid) or combined miRNA (0.25 µg or 0.5 µg each plasmid) overexpression. Twenty-four hours post 
transfection, cisplatin was added to the cell culture medium at a concentration of 20 µM. For apoptosis detection, live-cell assays were performed using Hoechst 33342 staining. 
Fluorescent cells were visualized by microscopy and apoptotic cells were counted from seven areas. Chemosensitization is indicated as a relative increase of apoptosis in 
cisplatin-treated cells compared to untreated cells (set as 1). Data shown in the bar plot are mean ± SD (n = 3). (B) The table shows the calculated fraction affected (fa) by the 
individual miRNA or combined miRNA treatments and the corresponding combination indexes (CI) of the combined treatments. fa is denoted by the relative increase of 
apoptotic tumour cells that is normalized to the treatment with cisplatin only (i.e., ctrl in +cDDP) and divided by the maximum increase of apoptosis in all listed treatments 
(synergism: CI < 1; antagonism: CI > 1). The estimated parameter values can be found in Table S6. (C) Western blot analyses show protein levels of E2F1 as well as BCL2 and Bax 
as survival and apoptosis markers. Actin was used as loading control and for normalisation to quantify protein bands (top of each immunoblot).  





The highest increase in apoptotic cells, however, 
was achieved when both miR-205-5p and miR-342-3p 
were co-expressed (each at 0.25 µg) in combination 
with cisplatin. When we increased the concentration 
of both miRNAs, the combined miRNA treatment 
(each at 0.5 µg) resulted in the highest increase of 
apoptosis compared to the experiments where we 
transfected miRNAs individually (each at 1 µg). We 
calculated the combination index and found that the 
combined treatment shows a synergistic effect (CI = 
0.134; Figure 6B). When we increased the cisplatin 
concentration to 40 µM, the combined miRNA 
treatment showed a synergistic effect (CI = 0.876) only 
at a low dose combination (Figure S3). At the protein 
level, the increased chemosensitivity of tumour cells, 
mediated by both miRNAs, was accompanied by 
reduced E2F1 and BCL2 expression and upregulated 
Bax (Figure 6C). Importantly, as E2F1 is upregulated 
in response to chemotherapy, the cooperating 
miR-205-5p and miR-342-3p exhibit the strongest 
chemosensitizing effect at a lower cisplatin 
concentration. According to our results, a combined 
administration of both miRNAs to improve cancer 
chemotherapy would not only enable but also make 
dose reduction of concomitant genotoxic drugs 
necessary.  
Conclusion  
Several studies have been conducted to explore 
miRNA-based therapies with the goal to improve 
outcomes of cancer treatment (51-54). For example, 
overexpression of miR-34a or knockdown of its direct 
and functional target CD44 can inhibit prostate cancer 
regeneration and metastasis (55). The simultaneous 
supplementation of miR-34 and let-7 in mouse models 
of non-small cell lung cancer results in a wide 
repression of key oncogenes and lead to a survival 
advantage (56). These therapies require a high 
specificity when targeting miRNAs or technologies to 
overcome physiological and cellular barriers to 
deliver miRNAs into targeted cells in case of miRNA 
replacement therapies. The efficient delivery of 
anti-miRNA agents using nanoparticle-based delivery 
vesicles was tested in a mouse model of lymphoma. 
The system was used to successfully inhibit the 
miR-155 oncomiR in vivo (57). However, miRNA 
replacement therapies can be compromised by 
off-target effects that induce unwanted gene 
regulation in other endogenous miRNA targets (58). 
We have shown that miRNA cooperativity reduces 
the total concentration of therapeutic miRNAs 
required to achieve a measurable gain of function, and 
therefore reduces off-target effects. 
In this article, we described the implementation 
of a systems biology approach that combines tools 
and algorithms from different disciplines to design 
therapeutic adjuvants for the treatment of 
chemoresistant tumours. The validity of this approach 
has been demonstrated using in vitro experiments, 
which lay the ground for further investigations in 
vivo. Further simulations and experimental data 
indicate that the cooperative repression of E2F1 by 
miR-205-5p and miR-342-3p has the potential to 
repress the growth of highly aggressive tumour cells 
overexpressing E2F1, and can also sensitize them to 
the administration of anticancer drugs. Our study 
suggests that therapies combining the administration 
of genotoxic drugs with miR-342-3p and miR-205-5p 
may enhance drug-induced apoptosis of cancer cells 
and reduce off-target effects. The proposed 
therapeutic strategy represents the first example that 
utilizes the effect of cooperative target regulation by a 
miRNA pair for anti-cancer purposes. 
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